Psychedelics and health behaviour change
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed to promote healthy behaviours are increasingly being studied, e.g., using psychobiological models of behavioural regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive and has been shown to predict favourable changes in patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics’ proposed mechanisms of action and research findings pertinent to health behaviour change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behaviour change methods (e.g., Cognitive Behaviour Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and well-being.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The "what" and "why" of goal pursuits: Human needs and the self-determination of behavior
Deci, E. L., & Ryan, R. M. (2000) · Psychological Inquiry · doi:10.1207/s15327965pli1104_01 · Cited by 34,210
Maslow, A. H. (1943) · Psychological Review · doi:10.1037/h0054346 · Cited by 21,563 · cited 1×
“Much the same as the five human needs, as defined by Maslow, may be necessary for human survival and development (Maslow, 1943), SDT posits that competence, autonomy and relatedness are innate essential psychological needs for mental health and for psychological growth.”
BackgroundExercise, physical activity, and self-determination theory: A systematic review
Teixeira, P. J., Carraça, E. V., Markland, D., Silva, M. N., & Ryan, R. M. (2012) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-9-78 · Cited by 2,963
Self-citationRising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century
Case, A., & Deaton, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518393112 · Cited by 2,759
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“A similar pattern was observed in the study of psilocybin for depression in cancer patients, from the same research group (Griffiths et al., 2016).”
BackgroundResultSelf-citationThe economic burden of physical inactivity: a global analysis of major non-communicable diseases
Ding, D., Lawson, K. D., Kolbe-Alexander, T. L., Finkelstein, E. A., Katzmarzyk, P. T., van Mechelen, W., & Pratt, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30383-x · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Ryan, R. M., & Deci, E. L. (2006) · Journal of Personality · doi:10.1111/j.1467-6494.2006.00420.x · Cited by 1,642
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 2×
“…et al., 2021; National Library of Medicine [NLM], 2017a, 2019b), anxiety (NLM, 2017b), substance use disorders (e.g., Bogenschutz et al., 2015; Johnson et al., 2014; Moreno et al., 2006), obsessive compulsive disorder (Moreno et al., 2006) and eating disorders (Carhart-Harris et al., 2021).”
BackgroundSelf-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“…planned or underway for a range of psychiatric conditions including cancer-related distress (Gasser et al., 2014, 2015; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), depression (e.g., Carhart-Harris et al., 2021; National Library of Medicine [NLM], 2017a, 2019b), anxiety…”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Ntoumanis, N., Ng, J. Y. Y., Prestwich, A., Quested, E., Hancox, J. E., Thøgersen-Ntoumani, C., Deci, E. L., Ryan, R. M., Lonsdale, C., & Williams, G. C. (2021) · Health Psychology Review · doi:10.1080/17437199.2020.1718529 · Cited by 1,154 · cited 1×
“Self-determined motivation is consistently associated with improved psychological wellbeing and with engagement with—and persistence in—a variety of tasks and long-term behaviours (Ntoumanis et al., 2020).”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“This line of research was resumed more recently, and results have tended to confirm the earlier observations with psilocybin for alcohol dependence (Bogenschutz et al., 2015), and extended it to tobacco smoking (Johnson et al., 2014, 2017b).”
BackgroundResultA-Tjak, J. G. L., Davis, M. L., Morina, N., Powers, M. B., Smits, J. A. J., & Emmelkamp, P. M. G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000365764 · Cited by 1,031 · cited 2×
“Looking forward, the therapeutic container for such work could be the ACE model (Accept, Connect, Embody) which was used to support patients undergoing psilocybin treatment for depression (Watts and Luoma, 2020) and is based on Acceptance and Commitment Therapy or ACT (A-Tjak et al., 2015).”
MethodPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 14×
“Alternatively, as highlighted above, Cognitive Behavioural Therapy (see also Wolff et al., 2020) and Motivational Enhancement Therapy (including Motivational Interviewing) could be used as therapeutic containers, as each of these has been supported by robust research as effective in supporting multiple varieties of he…”
BackgroundMethodResultInfluentialSelf-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 4×
“…of large-scale intrinsic networks (Carhart-Harris et al., 2016), increase in the repertoire of high-spatial frequency global brain states (Atasoy et al., 2018), and an increase in the communication between large-scale intrinsic networks (Carhart-Harris et al., 2016; Tagliazucchi et al., 2016).”
BackgroundInfluentialSelf-citationSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 3×
“, 2021; National Library of Medicine [NLM], 2017a, 2019b), anxiety (NLM, 2017b), substance use disorders (e.g., Bogenschutz et al., 2015; Johnson et al., 2014; Moreno et al., 2006), obsessive compulsive disorder (Moreno et al.”
BackgroundGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 1×
“…psychotherapy has been published or is now being planned or underway for a range of psychiatric conditions including cancer-related distress (Gasser et al., 2014, 2015; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), depression (e.g., Carhart-Harris et al., 2021; National…”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Self-citationWatts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 7×
“…Noorani et al. (2018) found insights into self-identity (e.g., unveiling of true self, and honesty with oneself) to result from sessions, and Watts et al. (2017) reported increased connection to self and feeling more attuned with ones’ internal needs and inherent worth as central…”
BackgroundInfluentialSelf-citationJakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536 · cited 4×
“The clinical studies reviewed have utilized preparation, monitoring and some form of integration (Johnson et al., 2008).”
BackgroundInfluentialTeixeira, P. J., Marques, M. M., Silva, M. N., Brunet, J., Duda, J. L., Haerens, L., La Guardia, J., Lindwall, M., Lonsdale, C., Markland, D., et al. (2020) · Motivation Science · doi:10.1037/mot0000172 · Cited by 528
Self-citationJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 1×
“A sense of unity, which might be conceptualized as an ultimate level of relatedness, is one of the features of the mystical experience construct that is strongly affected by classic psychedelics (Johnson et al., 2019).”
BackgroundSelf-citationIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 1×
“…of large-scale intrinsic networks (Carhart-Harris et al., 2016), increase in the repertoire of high-spatial frequency global brain states (Atasoy et al., 2018), and an increase in the communication between large-scale intrinsic networks (Carhart-Harris et al., 2016; Tagliazucchi et al., 2016).”
BackgroundSelf-citationHartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 1×
“Psychedelics may also enhance creative thinking (Kuypers et al., 2016) during acute states, depending on the context in which the experience takes place (Hartogsohn, 2016).”
BackgroundPatrick, H., & Williams, G. C. (2012) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-9-18 · Cited by 481 · cited 8×
“Motivational Interviewing in particular is largely consistent with SDT (Patrick and Williams, 2012), and both have a range of intervention techniques (e.”
BackgroundInfluentialMotivation, self-determination, and long-term weight control
Teixeira, P. J., Silva, M. N., Mata, J., Palmeira, A. L., & Markland, D. (2012) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-9-22 · Cited by 422 · cited 2×
“…concept has been explored in studies in health behaviour change, in areas such as dental hygiene (Halvari et al., 2019), diet, exercise and obesity (Teixeira et al., 2012a), diabetes (Phillips and Guarnaccia, 2020) and tobacco cessation (Williams et al., 2016), with generally encouraging results…”
ResultSelf-citationIncreased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017) · Scientific Reports · doi:10.1038/srep46421 · Cited by 410
Self-citationMediators of Weight Loss and Weight Loss Maintenance in Middle‐aged Women
Teixeira, P. J., Silva, M. N., Coutinho, S. R., Palmeira, A. L., Mata, J., Vieira, P. N., Carraça, E. V., Santos, T. C., & Sardinha, L. B. (2010) · Obesity · doi:10.1038/oby.2009.281 · Cited by 404 · cited 1×
“Although current lifestyle behaviour change interventions (e.g., for weight loss or diabetes) involve a wide variability of formats and length, a programme of several weeks (sometimes months) with regular educational sessions in a group setting is a very common model (e.g., Teixeira et al., 2010).”
BackgroundSelf-citationPreller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360 · cited 2×
“5 year follow-up of cancer patients who underwent psilocybin-assisted therapy showed persisting increases in not just well-being/life satisfaction (reported by 86% of participants, n=12) but also in ‘positive behaviour changes’ attributed to the psilocybin experience (100% of participants, n=14) (Agin-Liebes et al., 2…”
BackgroundPsychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Acceptance and Commitment Therapy (ACT) to reduce depression: a systematic review and meta-analysis
Bai, Z., Luo, S., Zhang, L., Wu, S., & Chi, I. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.040 · Cited by 321 · cited 1×
“In fact, Walsh and Thiessen (2018) have also proposed that psychedelic therapy should incorporate Acceptance and Commitment Therapy, a framework which has also been used for different mental and physical health problems, including obesity (Lawlor et al., 2020) and depression (Bai et al., 2020).”
BackgroundLSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · cited 6×
“It suggests that human beings are naturally inclined to ‘engage in interesting activities, to exercise capacities, to pursue connectedness in social groups, and to integrate intrapsychic and interpersonal experiences into a relative unity’ (Deci and Ryan, 2000) but this will occur only to the extent basic psychologica…”
BackgroundInfluentialSelf-citationPsychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Self-citationPsychedelics and connectedness
Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4701-y · Cited by 265
Self-citationReviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581980 · Cited by 229
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201 · cited 1×
“Psychedelics may also enhance creative thinking (Kuypers et al., 2016) during acute states, depending on the context in which the experience takes place (Hartogsohn, 2016).”
BackgroundHarmonic brain modes: a unifying framework for linking space and time in brain dynamics
Atasoy, S., Deco, G., Kringelbach, M. L., & Pearson, J. (2018) · The Neuroscientist · doi:10.1177/1073858417728032 · Cited by 124
Lawlor, E. R., Islam, N., Bates, S., Griffin, S. J., Hill, A. J., Hughes, C. A., Sharp, S. J., & Ahern, A. L. (2020) · Obesity Reviews · doi:10.1111/obr.13013 · Cited by 103 · cited 2×
“In fact, Walsh and Thiessen (2018) have also proposed that psychedelic therapy should incorporate Acceptance and Commitment Therapy, a framework which has also been used for different mental and physical health problems, including obesity (Lawlor et al., 2020) and depression (Bai et al., 2020).”
BackgroundOna, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76 · cited 2×
“In a recent observational study, 380 ayahuasca users were interviewed face to face and asked about their health (including height and weight, allowing for calculation of their body mass index (BMI)) and also their physical activity, diet and yoga/meditation habits (Ona et al., 2019).”
Background
Cited by
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
“cognitive behavioral therapy, psychedelics might offer a strong potential for fostering a healthier lifestyle, including improved diet, physical exercise, and mindfulness practices (Teixeira et al., 2022).”
History repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“While results from ongoing well-powered double-blind randomized controlled trials (RCTs) will determine whether psychedelic therapy translates into clinical benefits for nonpsychotic disorders in clinical psychiatry (11, 12), it has been proposed that psychedelic therapy may have broad therapeutic benefits via the att…”
BackgroundKohek, M., Ona, G., van Elk, M., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2077155 · Cited by 24
Metadata
- Authors
- Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzoe, D., Douglass, H., Kettner, H., & Carhart-Harris, R. L.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-05-29
- Volume
- 36
- Issue
- 1
- Pages
- 12-19
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3164067847
- Cited by
- 87
- References
- 49
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.